AIM-listed biotechnology business ReGen Therapeutics is poised for new funding after announcing bullish test results for its Colostrinin Alzheimer’s treatment.
AIM-listed biotechnology business ReGen Therapeutics is poised for new funding after announcing bullish test results for its Colostrinin Alzheimer’s treatment.
ReGen, which rekindled interest last year with test results suggesting its Zolpidem insomnia treatment could sometimes reverse the effects of brain damage, is now to present its latest findings on Colostrinin to the Eighth International Conference on Alzheimer’s and Parkinson’s Diseases at Salzburg in Austria next month.
The company says a study has shown Colostrinin increases the life-span and improves the neurological performance of ‘inbred mice predisposed to premature ageing’.
Percy Lomax, ReGen’s indefatigably cheerful executive chairman, comments: ‘In developing our nutraceutical product Colostrinin, we are looking to help improve people’s quality of life. This study shows that, with respect to ageing and neurological functions, we may be able to do that.’
